Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GWT-Tud GmbH
Sponsor

GWT-Tud GmbH

Germany Freiberger Strasse 33, Wilsdruffer Vorstadt/seevorstadt-West, 01067 Dresden, Germany

About the sponsor

Research activity includes treatment of anemia in adults with lower-risk myelodysplastic syndromes, especially those with ring sideroblasts who depend on red blood cell transfusions and have limited response to prior erythropoiesis-stimulating agents.

  • Transfusion-dependent anemia
  • Red blood cell transfusion independence
  • Lower-risk MDS

The sponsor’s work in this area centers on hematologic disease management and the clinical burden of chronic transfusion needs.

About Specializations

GWT-Tud GmbH runs clinical trials in conditions such as Myelodysplastic syndrome, Factor VIII deficiency, Synovitis, B-cell lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Acute myeloid leukaemia+1

Not recruiting

Study Comparing CPX-351 and Conventional Drug Combination for Patients with High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia Before Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:GWT-Tud GmbH

Bone marrow disorder+1

Not recruiting

Study on the Effectiveness and Safety of Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:GWT-Tud GmbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.